British journal of clinical pharmacology
-
Br J Clin Pharmacol · Dec 2003
Randomized Controlled Trial Clinical TrialNo clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Voriconazole is a new triazole antifungal agent, and is metabolized by the cytochrome P450 isoenzymes CYP2C9, CYP2C19 and to a lesser extent by CYP3A4. Protease inhibitors, such as indinavir, are also metabolized by cytochrome P450 (mainly CYP3A4). As these drugs are likely to be coadministered, these studies were performed to assess the pharmacokinetic interactions, safety and toleration of these drugs when taken together. ⋯ The coadministration of voriconazole and indinavir in healthy volunteers had no clinically significant effect on the pharmacokinetics of either voriconazole or indinavir.